Azenta, Inc. AZTA R2KR3KPHARMA
Company Overview
Azenta, Inc. provides biological and chemical compound sample exploration and management solutions for the life sciences industry in the United States, China, the United Kingdom, rest of Europe, the Asia Pacific, and internationally. It operates through Sample Management Solutions and Multiomics segments. The Sample Management Solutions segment provides sample management products and services, including automated stores, cryogenic systems, automated sample tubes, consumables and instruments, and controlled rate thawing devices, as well as sample repository services. This segment also offers consultation services to clients throughout their experimental design and implementation processes. The Multiomics segment provides genomic and other sample analysis services comprising gene sequencing, gene synthesis, and related services. The company has a strategic partnership with Frontier Space Ltd to conduct scientific experiments in space. The company was formerly known as Brooks Automation, Inc. and changed its name to Azenta, Inc. in December 2021. Azenta, Inc. was founded in 1978 and is headquartered in Burlington, Massachusetts.
Why Investors Should Care
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Sep 2025 Revenue of $593.82M (+3.6% YoY); net profit $-55.76M.
- Trailing 12 Months Year-on-year growth — revenue +12.0%.
- 5-Year Trend Long-term compounding — revenue CAGR 6.9%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 6.89% |
| 1 Year: | 12.00% |
Stock Price Performance
| 1 Year: | -2.34% |
| 6 Months: | +28.93% |
| 3 Months: | +38.08% |
| 1 Month: | +1.92% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- Golden Cross9d ago
- RSI (14)47.28 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | AZTA Azenta, Inc. R2KR3KPHARMA | 31.33 | -12.74 | $1.44B | 0.00% | -1.19% | -7.04% | 6.89% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,149.36 | 38.57 | $1.02T | 0.58% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 275.23 | 31.97 | $663.28B | 2.09% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 256.46 | 72.45 | $453.19B | 2.84% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 150.33 | 120.26 | $371.29B | 2.65% | - | 34.70% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 397.14 | 25.54 | $356.47B | 2.33% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 159.99 | 24.20 | $304.10B | 3.03% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 162.70 | 24.36 | $252.33B | 1.98% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 437.23 | 27.14 | $235.98B | 2.49% | 13.95% | 91.47% | 5.51% | 5.55% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Dec 2014 | Mar 2015 | Jun 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | 142.60M | 156.95M | 172.36M | 179.37M | 198.39M | 203.88M | 91.69M | 95.30M | 93.30M | 108.25M | 118.14M | 129.53M | 129.09M | 136.94M | 139.65M | 145.54M | 132.74M | 178.37M | 148.40M | 165.95M | 142.20M | 136.35M | 144.29M | - | - | 143.34M | 143.94M | 158.95M | 148.64M | 144.79M | 161.18M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 80.56M | 76.18M | 90.99M | 84.94M | 82.76M | - |
| Gross Profit | 39.09M | 46.02M | 51.19M | 40.55M | 46.80M | 54.16M | 56.94M | 64.52M | 71.57M | 54.26M | 62.39M | 66.81M | 72.08M | 80.52M | 83.51M | 38.69M | 41.66M | 39.26M | 52.54M | 57.34M | 57.90M | 62.43M | 66.14M | 67.04M | 70.83M | 59.60M | 73.86M | 53.24M | 68.00M | 61.77M | 59.78M | 64.59M | - | - | 62.78M | 67.76M | 67.96M | 63.71M | 62.03M | 72.36M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 77.40M | 67.72M | 66.18M | 69.80M | 77.32M | - |
| Operating Income | -6.48M | 3.05M | 10.17M | -8.32M | -6.34M | 8.49M | 13.16M | 14.80M | 18.77M | 4.92M | 10.32M | 12.55M | 5.33M | 13.67M | 16.42M | -12.02M | -11.14M | -12.05M | -1.38M | 356.00K | -9.32M | -883.00K | -21.24M | -325.00K | -4.71M | -5.07M | -27.68M | -12.98M | -15.84M | -14.86M | -24.68M | -7.11M | - | - | -14.61M | 40.00K | 1.78M | -6.09M | -15.29M | -4.18M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -661.00K | 14.76M | 16.21M | 7.55M | -1.28M | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -12.55M | 3.44M | 5.78M | -2.06M | -157.34M | - |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 7.24M | 2.76M | -45.61M | 3.13M | -323.00K | - |
| Net Income | -2.73M | 2.71M | 7.68M | -4.65M | -83.94M | 8.56M | 13.87M | 14.01M | 17.35M | 16.49M | 67.02M | 22.72M | 14.41M | 3.42M | 7.25M | 13.06M | 9.13M | 13.70M | 28.97M | 26.03M | 23.75M | 39.17M | 21.80M | 43.32M | 2.12B | -9.57M | -11.23M | -4.93M | -1.47M | -14.26M | -137.44M | -6.55M | - | - | -47.66M | -52.81M | 50.84M | -15.43M | -160.80M | 2.46M |
| Diluted EPS | -0.04 | 0.04 | 0.11 | -0.07 | -1.22 | 0.12 | 0.20 | 0.20 | 0.25 | 0.23 | 0.95 | 0.32 | 0.20 | 0.05 | 0.10 | 0.18 | 0.12 | 0.19 | 0.39 | 0.35 | 0.32 | 0.53 | 0.29 | 0.58 | 28.28 | -0.13 | -0.15 | -0.07 | -0.02 | -0.25 | -2.48 | -0.12 | - | - | -0.88 | -1.15 | 1.02 | -0.34 | -3.49 | 0.05 |
| R&D Expense | 13.49M | 12.68M | 12.83M | 13.28M | 13.11M | 12.82M | 10.85M | 11.35M | 11.96M | 11.40M | 11.35M | 12.04M | 13.15M | 14.10M | 14.23M | 14.40M | 15.32M | 14.00M | - | 5.09M | 5.24M | 5.49M | - | 6.49M | 6.90M | 6.51M | 7.54M | 8.52M | 8.97M | 7.99M | 8.41M | 7.59M | 7.54M | 7.11M | 7.60M | 7.42M | 8.26M | 9.19M | 9.43M | 8.85M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Sep 2009 | Sep 2010 | Sep 2011 | Sep 2012 | Sep 2013 | Sep 2014 | Sep 2015 | Sep 2016 | Sep 2017 | Sep 2018 | Sep 2019 | Sep 2020 | Sep 2021 | Sep 2022 | Sep 2023 | Sep 2024 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 218.71M | 592.97M | 688.11M | 488.98M | 422.44M | 482.85M | 552.71M | 434.01M | 527.50M | 631.56M | 334.18M | 388.54M | - | 555.50M | 551.49M | 573.45M | 593.82M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | 299.91M | 312.28M | 318.83M | 323.54M |
| Gross Profit | -6.00M | 166.29M | 223.02M | 159.45M | 132.31M | 167.34M | 189.10M | 156.69M | 198.89M | 246.08M | 134.60M | 172.15M | - | 255.58M | 239.21M | 254.62M | 270.28M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | 279.01M | 295.88M | 294.48M | 291.95M |
| Operating Income | -228.03M | 47.01M | 79.60M | 1.64M | -16.80M | -2.70M | 16.89M | -17.05M | 14.32M | 31.41M | -47.43M | -36.60M | - | -23.42M | -56.67M | -39.86M | -21.67M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | 30.28M | 28.91M | 50.88M | 39.54M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | 2.04M | 4.59M | 0 | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | -9.94M | -20.00M | -19.12M | -7.14M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.35M | -11.96M | 5.24M | -31.60M |
| Net Income | -227.86M | 59.84M | 130.38M | 136.79M | -2.21M | 31.36M | 14.22M | -69.48M | 62.61M | 116.58M | 437.42M | 64.85M | - | 2.13B | -14.64M | -164.90M | -55.76M |
| Diluted EPS | -3.62 | 0.93 | 2.01 | 2.08 | -0.03 | 0.46 | 0.21 | -1.01 | 0.89 | 1.64 | 6.04 | 0.88 | - | 28.48 | -0.22 | -3.60 | -1.30 |
| R&D Expense | 31.61M | 31.16M | 39.85M | 44.72M | 46.21M | 52.65M | 52.23M | 44.24M | 39.88M | 46.94M | 17.32M | 17.82M | 22.41M | 27.54M | 32.14M | 31.52M | 30.39M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Sep 2008 | Sep 2009 | Sep 2010 | Sep 2011 | Sep 2012 | Sep 2013 | Sep 2014 | Sep 2015 | Sep 2016 | Sep 2017 | Sep 2018 | Sep 2019 | Sep 2020 | Sep 2021 | Sep 2022 | Sep 2023 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 518.22M | 636.96M | 741.96M | 736.76M | 778.04M | 758.70M | 685.90M | 766.63M | 1.10B | 1.52B | 1.56B | - | 3.72B | 2.89B | 2.10B | 2.04B | 2.03B | 2.02B | 2.06B |
| Current Assets | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 2.46B | 1.42B | 833.03M | - | - | - | 708.34M |
| Cash & Equivalents | 110.27M | 59.98M | 59.82M | 58.83M | 54.64M | 82.97M | 94.11M | 80.72M | 85.09M | 101.62M | 197.71M | 256.64M | 250.65M | - | 658.27M | 678.91M | 280.03M | - | - | - | 279.78M |
| Inventory | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 85.54M | 128.20M | 71.32M | - | - | - | 74.96M |
| Receivables | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 163.76M | 156.53M | 154.17M | - | - | - | 142.18M |
| Total Liabilities | - | - | 128.87M | 118.02M | 92.66M | 104.11M | 135.15M | 126.66M | 132.22M | 158.98M | 377.43M | 377.05M | 345.65M | - | 352.74M | 351.22M | 332.42M | 322.60M | 338.56M | 345.98M | 332.60M |
| Current Liabilities | - | - | 108.16M | 95.74M | 81.19M | 92.56M | 113.84M | 113.00M | 119.79M | 146.78M | 164.62M | 272.27M | 211.12M | - | 230.55M | 210.93M | 206.09M | 202.52M | 221.05M | 246.17M | 237.67M |
| Long Term Debt | - | - | - | - | - | - | - | - | - | - | 194.07M | 50.31M | 49.59M | 49.68M | - | - | - | - | - | - | - |
| Total Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 49.23M | 60.44M | 56.68M | - | - | - | 51.24M |
| Total Equity | 542.40M | 317.87M | 388.81M | 518.35M | 648.67M | 631.96M | 642.89M | 632.04M | 553.69M | 607.64M | 717.83M | 1.14B | 1.21B | - | 3.36B | 2.53B | 1.77B | 1.72B | 1.70B | 1.67B | 1.73B |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 88.48M | 71.29M | 59.03M | - | - | - | 59.32M |
Cash Flows (Annual)
Figures in USD.
| Metric | Sep 2009 | Sep 2010 | Sep 2011 | Sep 2012 | Sep 2013 | Sep 2014 | Sep 2015 | Sep 2016 | Sep 2017 | Sep 2018 | Sep 2019 | Sep 2020 | Sep 2021 | Sep 2022 | Sep 2023 | Sep 2024 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -56.49M | 27.87M | 87.65M | 36.04M | 54.39M | 53.78M | 43.73M | 39.55M | 96.22M | 73.96M | 90.90M | 37.87M | - | -466.05M | 5.83M | 49.74M | 72.18M |
| Investing Cash Flow | 6.25M | -29.21M | -84.25M | -21.04M | -7.15M | -17.80M | -17.64M | -10.87M | -54.19M | -148.47M | 211.31M | -22.74M | - | 1.47B | 431.38M | 224.74M | -90.46M |
| Financing Cash Flow | 1.25M | 1.25M | -3.82M | -19.25M | -19.48M | -24.46M | -34.01M | -25.96M | -25.92M | 170.28M | -191.16M | -27.02M | - | -62.76M | -840.46M | -659.21M | -9.59M |
| Capital Expenditure | -11.34M | -3.47M | -6.46M | -8.65M | -3.63M | -5.52M | -16.15M | -12.85M | -12.68M | -12.79M | -23.86M | -39.92M | - | -77.44M | -39.44M | -37.39M | -33.86M |
| Free Cash Flow | -67.83M | 24.40M | 81.19M | 27.39M | 50.75M | 48.26M | 27.58M | 26.70M | 83.55M | 61.18M | 67.04M | -2.06M | - | -543.48M | -33.60M | 12.35M | 38.32M |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - | - | - | - | 936.78M | -403.24M | -384.73M | -27.87M |
| Share Buybacks | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 838.51M | 661.70M | 0 |
Ratios (Annual)
Figures in %.
| Metric | Sep 2009 | Sep 2010 | Sep 2011 | Sep 2012 | Sep 2013 | Sep 2014 | Sep 2015 | Sep 2016 | Sep 2017 | Sep 2018 | Sep 2019 | Sep 2020 | Sep 2021 | Sep 2022 | Sep 2023 | Sep 2024 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | -2.7% | 28.0% | 32.4% | 32.6% | 31.3% | 34.7% | 34.2% | 36.1% | 37.7% | 39.0% | 40.3% | 44.3% | - | 46.0% | 43.4% | 44.4% | 45.5% |
| Operating Margin % | -104.3% | 7.9% | 11.6% | 0.3% | -4.0% | -0.6% | 3.1% | -3.9% | 2.7% | 5.0% | -14.2% | -9.4% | - | -4.2% | -10.3% | -7.0% | -3.6% |
| Net Margin % | -104.2% | 10.1% | 18.9% | 28.0% | -0.5% | 6.5% | 2.6% | -16.0% | 11.9% | 18.5% | 130.9% | 16.7% | - | 384.0% | -2.7% | -28.8% | -9.4% |
| ROE % | -71.7% | 15.4% | 25.2% | 21.1% | -0.4% | 4.9% | 2.2% | -12.5% | 10.3% | 16.2% | 38.4% | 5.3% | - | 63.4% | -0.6% | -9.3% | -3.2% |
| ROCE % | - | 11.5% | 14.7% | 0.2% | -2.6% | -0.4% | 2.6% | -3.0% | 2.3% | 3.4% | -3.8% | -2.7% | - | -0.7% | -2.1% | -2.1% | -1.2% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 17.19% | 7.53M | $248.10M |
| 2 | Politan Capital Management LP | 10.55% | 4.62M | $152.31M |
| 3 | Vanguard Portfolio Management LLC | 5.69% | 2.49M | $82.17M |
| 4 | Vanguard Capital Management LLC | 4.27% | 1.87M | $61.62M |
| 5 | State Street Corporation | 4.25% | 1.86M | $61.29M |
| 6 | Massachusetts Financial Services Co. | 3.25% | 1.42M | $46.91M |
| 7 | Shaw D.E. & Co., Inc. | 3.06% | 1.34M | $44.19M |
| 8 | Morgan Stanley | 3.04% | 1.33M | $43.83M |
| 9 | Front Street Capital Management, Inc. | 2.97% | 1.30M | $42.88M |
| 10 | Dimensional Fund Advisors LP | 2.81% | 1.23M | $40.61M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for AZTA
Why Azenta (AZTA) Stock Is Down Today - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMilgFBVV95cUxOOTRHczFHY0NlZ2p6VXRUNVZ0S0IyYWVyNy1uTm1BbWJtU3ltdVVuQ1lFaVBGbERaOWp6cUlsNjEwdWxKa3Zid0ZVdlJ2TVRuT2lZWmJCZ2dEVzhCNXFoeW5rZGdDclZqZC1DV0ZPWURYQjlzTGFjb04tUHgtNjlHYzg3cEhLdFhHT3lrVj…
A $63 million sale is now fully paid in cash. Azenta received the final $35 million. - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivwFBVV95cUxPMnhnSVE0NHZEcjNGZEV3bFNrZjJ3XzlBWHpjM3NxdFhsWHhGa280WnMtdXBiaG5TQUtEV0Q4ci16bG9LV1VrOXFKOEdrUjNJQW1IMXRuVHpWdXFwQm11WkItRXBJS2JvRnI5Sjhhb3NRVnpqeTZySGNLb21NUmtyR3J1Ym02LUI2aVhENW…
Is Azenta (AZTA) Undervalued Following Its CEO Change? - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi0AFBVV95cUxQamtKRndpbkUyb3RwTlF6SEl0blAxeHkzTS1MaHN6bEtDVWNJVlRmbkhnbWpBME5HenAyQWJXTmtjR3A4Vl9iX01VOFlESVUzR2JjbnpqVERlaHJneGlFcGN3OC1SeS00Z3Q4UHVNaFZmdU54TG9ocUlpVEZjbWFaNmFEdk1CUy1qRWdLQU…
Azenta Completes B Medical Divestiture With Loan Repayment - The Globe and Mail
<a href="https://news.google.com/rss/articles/CBMi3gFBVV95cUxNR09PbmpnOFNTU0tFWXVmM29VRXV5MDcwajlCUGZhSHQ0b29xcEtjWXpuR0dHS0Q3b0gwTDI1YmtRUWhJYWJHSWpKUUZKTHBGaFZiMXVzMmVwbHFuZFlFVll1dnZMbk90akNkaDZ3d2lzM2hRS0ZSVXJEbWdFVHdqN3FZRFN0WXFhcVhvNW…
Azenta Stock (AZTA) Opinions on Analyst Trading Signals - quiverquant.com
<a href="https://news.google.com/rss/articles/CBMilwFBVV95cUxPekQ0RkFtaFYzRk1rRkNjcFRCaF8yZk5pV0ZDUW0xeDRpeTdhNjhuM2pVdVJIQ2VWdGY1VGhZU2FERG5vU3JhQXFnTVIyZndIaDdEMlB4MVVzNjFXeWpWWUxnUG0tQm9JWUsxNlNEUkJBU1htRXhpUDZTRWhoWF96NUQ5ZG9TcUtaNFE3aS…
Azenta completes B Medical sale as vendor loan repaid (AZTA) - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMikgFBVV95cUxPVFV5V1NrVmxpTnBiaGVrb29mLUlxdmhSdl8zNHBUajRSRTBaZlZMMUgxMnhUNWlBT1ZLMkloZ3lHM1NOTlYyOGZFX21pcDNlTnlGQUIxQzNHSVV0TWZnY2hyWV9HYTBWd0FNa2trVUVHdUNuTUV4elhYdGNFN1AzcXFBRXBTVUJIeFFuQV…
AZTA — Frequently Asked Questions
What is the current share price of Azenta, Inc. (AZTA)?
As of 2026-09-07 16:24 PDT, Azenta, Inc. (AZTA) trades at $31.33 on NasdaqGS. Its 52-week range is $16.02 to $41.01.
What is the market capitalisation of AZTA?
Azenta, Inc. (AZTA) has a market capitalisation of $1.44B on NasdaqGS.
What is the P/E ratio of AZTA?
AZTA trades at a trailing price-to-earnings (P/E) ratio of -12.74. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 0.93.
What is the return on equity (ROE) of AZTA?
AZTA has a return on equity (ROE) of -7.04%. Its return on capital employed (ROCE) is -1.19%.
Is AZTA a good stock to buy?
This page provides a data-driven analysis of Azenta, Inc. (AZTA), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.